Altcoin Asset 13 Relative Strength Momentum Rotation Strategy
Identifies high-beta outperforming altcoins displaying structural alpha against Bitcoin during market expansion regimes. Backtest, deploy, and forward-test live on Altcoin Asset 13 (ALT13) with automated 1:2 risk brackets and institutional cost accounting before risking a dollar.
Free forever paper tier · Live Binance spot prices · Non-custodial · No card required
Quantitative Specifications for ALT13
Filtered by market state. Stands down during unverified regimes to defend equity.
Typical duration from signal confirmation to take-profit or defensive stop exit.
Pre-calculated bracket parameters balancing win-rate expectancy against drawdown.
Mathematical Engine & Formula
RS = (AssetPrice_t / AssetPrice_{t-30}) / (BTCPrice_t / BTCPrice_{t-30})Entry Condition: Asset 30-day relative strength exceeds 1.20 and daily volume ranks in the top quartile of Binance spot pairs.
Exit Condition: Rotate capital into stablecoins or BTC when 7-day relative momentum decelerates below parity (1.00).
Execution & Cost Transparency
Most backtests fabricate impossible returns by assuming zero fees and zero slippage. Zengtrade factors realistic market realities into every paper trade on Altcoin Asset 13:
- Spot Friction: Rebalancing costs apply during sector rotations. Maintain disciplined trade frequency.
- Slippage Buffer: Modeled with volume-weighted order book depth.
- Kill Switch: Position auto-closes if volatility breaks maximum daily threshold.
Authored & Verified by Zengtrade Quantitative Research: Every model parameter for Altcoin Asset 13 (ALT13) is calibrated on historical Binance spot tick archives with a 35 bps round-trip friction model (exchange fees, spread, and slippage buffer). Zengtrade operates under a strict non-custodial, paper-first mandate: we never hold client deposits, never charge commissions on trading volume, and never fabricate hypothetical return curves. Forward-test evidence must be established before live deployment. Read our Regime Engine Methodology and Risk Disclosures.